The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD.
- Priority targets for this program are alpha-synuclein and neuroinflammation, but applications may focus on other promising therapeutic targets.
- Imaging modalities can include PET, SPECT and MRI.
- Projects should aim to develop novel imaging biomarkers as opposed to prospectively collecting data using existing technologies. Prospective data collection is appropriate only if a novel imaging technique or tracer is being tested. Novel data analysis techniques may be proposed but should utilize existing data sets.
- Examples of projects that are appropriate for this program include development of novel PET or SPECT tracers, early validation of new tracers, and development and validation of novel MRI techniques.
Watch a previously recorded webinar on our Foundation's funding strategy and opportunities, and the application and review processes